206 related articles for article (PubMed ID: 36903539)
1. Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles.
Ali AM; Makki AA; Ibraheem W; Abdelrahman M; Osman W; Sherif AE; Ashour A; Ibrahim SRM; Ghazawi KF; Samman WA; Alzain AA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903539
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
3. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Umbralisib: First Approval.
Dhillon S; Keam SJ
Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
7. Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach.
Kumar BH; Manandhar S; Choudhary SS; Priya K; Gujaran TV; Mehta CH; Nayak UY; Pai KSR
Mol Divers; 2023 Oct; 27(5):2015-2036. PubMed ID: 36244040
[TBL] [Abstract][Full Text] [Related]
8. Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma.
Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH; Wang NY
Bioorg Chem; 2020 Dec; 105():104344. PubMed ID: 33091667
[TBL] [Abstract][Full Text] [Related]
9. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Kienle DL; Stilgenbauer S
Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
11. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
12. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
Vanhaesebroeck B; Khwaja A
Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
[TBL] [Abstract][Full Text] [Related]
13. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
14. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.
Schatz JH
Curr Oncol Rep; 2011 Oct; 13(5):398-406. PubMed ID: 21755275
[TBL] [Abstract][Full Text] [Related]
16. BRCA1/TP53 tumor proteins inhibited by novel analogues of curcumin - Insight from computational modelling, dynamic simulation and experimental validation.
Aloor LJ; Skariyachan S; Raghavamenon AC; Kumar KM; Narayanappa R; Uttarkar A; Niranjan V; Cherian T
Int J Biol Macromol; 2023 Dec; 253(Pt 4):126989. PubMed ID: 37739292
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the New Inhibitors by Sulfadiazine and Modified Derivatives of α-D-glucopyranoside for White Spot Syndrome Virus Disease of Shrimp by In Silico: Quantum Calculations, Molecular Docking, ADMET and Molecular Dynamics Study.
Kumer A; Chakma U; Rana MM; Chandro A; Akash S; Elseehy MM; Albogami S; El-Shehawi AM
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744817
[TBL] [Abstract][Full Text] [Related]
18. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
19. Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles.
Edris A; Abdelrahman M; Osman W; Sherif AE; Ashour A; Garelnabi EAE; Ibrahim SRM; Bafail R; Samman WA; Ghazawi KF; Mohamed GA; Alzain AA
Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233624
[TBL] [Abstract][Full Text] [Related]
20. Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282.
Verma MK; Samant C; Kale R; Patra S; Mahajan N; Gholve MK; Marisetti A; Sunkara B; Naik A; Shingare M; Reddy M; Bokare AM; Akarte A; Koul S; Nigade PB; Patil VB; Modi D; Ahirrao P; Pawar S; Kuldharan S; Dinchhana L; Mehta M; Gundu J; Jana N; Vidhate P; Mahangare SJ; Shukla MR; Goel RN; Bhonde M; Kamboj RK; Palle VP
Biochem Biophys Res Commun; 2022 Dec; 637():267-275. PubMed ID: 36410276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]